Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Management Using the Latest Technologies in Resource-limited Settings to Optimize Combination Therapy After Viral Failure (MULTI-OCTAVE)

Next Previous
X
Search
Trial Profile

Management Using the Latest Technologies in Resource-limited Settings to Optimize Combination Therapy After Viral Failure (MULTI-OCTAVE)

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 09 May 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atazanavir/ritonavir (Primary) ; Darunavir (Primary) ; Emtricitabine/tenofovir disoproxil fumarate (Primary) ; Etravirine (Primary) ; Lopinavir/ritonavir (Primary) ; Raltegravir (Primary) ; Ritonavir (Primary)
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms MULTI-OCTAVE

    • Most Recent Events

    • 13 Oct 2023 According to Janssen Pharmaceuticals media release, Janssen Pharmaceuticals has changed its name to Johnson & Johnson Innovative Medicine.
    • 06 Apr 2021 Results of sub analysis from cohort A, evaluating associations between antiretroviral hair concentrations, self-reported adherence, and subsequent virologic outcomes, published in the AIDS
    • 10 Jul 2020 Results presented at the 23rd International AIDS Conference

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top